{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:41:50Z","timestamp":1792885310342,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40744-019-0146-6","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T13:16:08Z","timestamp":1550668568000},"page":"165-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy"],"prefix":"10.1007","volume":"6","author":[{"given":"Philip C.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"issue":"4","key":"146_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"146_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/art.1780280107","volume":"28","author":"MA Khan","year":"1985","unstructured":"Khan MA, van der Linden SM, Kushner I, Valkenburg HA, Cats A. Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients. Arthritis Rheum. 1985;28(1):40\u20133.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"146_CR3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Landewe R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68(6):770\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"146_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"146_CR5","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/art.38776","volume":"66","author":"A Deodhar","year":"2014","unstructured":"Deodhar A, Reveille JD, van den Bosch F, et al. The concept of axial spondyloarthritis: joint statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis International Society in response to the US Food and Drug Administration\u2019s comments and concerns. Arthritis Rheumatol. 2014;66(10):2649\u201356.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"146_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10067-016-3261-6","volume":"35","author":"N Akkoc","year":"2016","unstructured":"Akkoc N, Khan MA. ASAS classification criteria for axial spondyloarthritis: time to modify. Clin Rheumatol. 2016;35(6):1415\u201323.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"146_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11926-015-0535-y","volume":"17","author":"S van der Linden","year":"2015","unstructured":"van der Linden S, Akkoc N, Brown MA, Robinson PC, Khan MA. The ASAS criteria for axial spondyloarthritis: strengths, weaknesses, and proposals for a way forward. Curr Rheumatol Rep. 2015;17(9):62.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"146_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/annrheumdis-2012-202073","volume":"72","author":"PC Robinson","year":"2013","unstructured":"Robinson PC, Wordsworth BP, Reveille JD, Brown MA. Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis. 2013;72(2):162\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"146_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11926-015-0515-2","volume":"17","author":"N Akkoc","year":"2015","unstructured":"Akkoc N, Khan MA. Looking into the new ASAS classification criteria for axial spondyloarthritis through the other side of the glass. Curr Rheumatol Rep. 2015;17(6):515.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"146_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/annrheumdis-2015-208852","volume":"75","author":"A Deodhar","year":"2016","unstructured":"Deodhar A, Strand V, Kay J, Braun J. The term \u2018non-radiographic axial spondyloarthritis\u2019 is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016;75(5):791\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"146_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/imj.12544","volume":"45","author":"PC Robinson","year":"2015","unstructured":"Robinson PC, Benham H. Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial spondyloarthritis. Intern Med J. 2015;45(2):127\u201333.","journal-title":"Intern Med J"},{"issue":"4","key":"146_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1053\/berh.2002.0250","volume":"16","author":"J Braun","year":"2002","unstructured":"Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2002;16(4):573\u2013604.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"146_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"MC Creemers","year":"2005","unstructured":"Creemers MC, Franssen MJ, van\u2019t Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"146_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","volume":"74","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, Stolwijk C, van Tubergen A, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12\u00a0year prospective follow-up of the OASIS study. Ann Rheum Dis. 2015;74(1):52\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"146_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jbspin.2015.04.001","volume":"82","author":"D Wendling","year":"2015","unstructured":"Wendling D, Claudepierre P, Pham T, Loeuille D, Prati C. MRI in axial spondyloarthritis: from light to shadow? Jt Bone Spine. 2015;82(5):302\u20134.","journal-title":"Jt Bone Spine"},{"issue":"4","key":"146_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/BOR.0b013e32832af481","volume":"21","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych WP. MRI in ankylosing spondylitis. Curr Opin Rheumatol. 2009;21(4):313\u20137.","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"146_CR17","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis. 2009;68(10):1520\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"146_CR18","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RG Lambert","year":"2016","unstructured":"Lambert RG, Bakker PA, van der Heijde D, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis. 2016;75(11):1958\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"146_CR19","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40475","volume":"70","author":"J de Winter","year":"2018","unstructured":"de Winter J, de Hooge M, van de Sande M, et al. Magnetic resonance imaging of the sacroiliac joints indicating sacroiliitis according to the Assessment of SpondyloArthritis International Society definition in healthy individuals, runners, and women with postpartum back pain. Arthritis Rheumatol. 2018;70(7):1042\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"146_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/rheumatology\/kex491","volume":"57","author":"G Varkas","year":"2018","unstructured":"Varkas G, de Hooge M, Renson T, et al. Effect of mechanical stress on magnetic resonance imaging of the sacroiliac joints: assessment of military recruits by magnetic resonance imaging study. Rheumatology (Oxford). 2018;57(3):508\u201313.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"146_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/art.40429","volume":"70","author":"U Weber","year":"2018","unstructured":"Weber U, Jurik AG, Zejden A, et al. Frequency and anatomic distribution of magnetic resonance imaging features in the sacroiliac joints of young athletes: exploring \u201cbackground noise\u201d toward a data-driven definition of sacroiliitis in early spondyloarthritis. Arthritis Rheumatol. 2018;70(5):736\u201345.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"146_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1136\/annrheumdis-2013-203425","volume":"73","author":"X Baraliakos","year":"2014","unstructured":"Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014;73(10):1819\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"146_CR23","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/ard.2011.150680","volume":"71","author":"KG Hermann","year":"2012","unstructured":"Hermann KG, Baraliakos X, van der Heijde DM, et al. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI study group. Ann Rheum Dis. 2012;71(8):1278\u201388.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"146_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/1754-9485.12573","volume":"61","author":"SL Truong","year":"2017","unstructured":"Truong SL, Saad NF, Robinson PC, et al. Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand. J Med Imaging Radiat Oncol. 2017;61(1):58\u201369.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"7","key":"146_CR25","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/rheumatology\/ket012","volume":"52","author":"M de Hooge","year":"2013","unstructured":"de Hooge M, van den Berg R, Navarro-Compan V, et al. Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: no added value of gadolinium compared with short tau inversion recovery sequence. Rheumatology (Oxford). 2013;52(7):1220\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"146_CR26","first-page":"2056","volume":"32","author":"KG Hermann","year":"2005","unstructured":"Hermann KG, Landewe RB, Braun J, van der Heijde DM. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: is paramagnetic contrast medium necessary? J Rheumatol. 2005;32(10):2056\u201360.","journal-title":"J Rheumatol"},{"issue":"5","key":"146_CR27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/1756-185X.12358","volume":"17","author":"PC Robinson","year":"2014","unstructured":"Robinson PC, Bird P, Lim I, et al. Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA). Int J Rheum Dis. 2014;17(5):548\u201356.","journal-title":"Int J Rheum Dis"},{"issue":"11","key":"146_CR28","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1002\/art.24024","volume":"58","author":"AN Bennett","year":"2008","unstructured":"Bennett AN, McGonagle D, O\u2019Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413\u20138.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"146_CR29","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"M Rudwaleit","year":"2008","unstructured":"Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67(9):1276\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"146_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3899\/jrheum.170312","volume":"45","author":"LA Bradbury","year":"2018","unstructured":"Bradbury LA, Hollis KA, Gautier B, et al. Diffusion-weighted imaging is a sensitive and specific magnetic resonance sequence in the diagnosis of ankylosing spondylitis. J Rheumatol. 2018;45(6):771\u20138.","journal-title":"J Rheumatol"},{"issue":"2","key":"146_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3899\/jrheum.170171","volume":"45","author":"R Sengupta","year":"2018","unstructured":"Sengupta R, Marzo-Ortega H, McGonagle D, Wadeley A, Bennett AN, British Society for Spondyloarthritis. Short-term repeat magnetic resonance imaging scans in suspected early axial spondyloarthritis are clinically relevant only in HLA-B27-positive male subjects. J Rheumatol. 2018;45(2):202\u20135.","journal-title":"J Rheumatol"},{"key":"146_CR32","doi-asserted-by":"publisher","unstructured":"Bakker PA, Ramiro S, Ez-Zaitouni Z, et al. Is it useful to repeat MRI of the sacroiliac joints after three months or one year in the diagnostic process of patients with chronic back pain suspected of axial spondyloarthritis? Arthritis Rheumatol. 2018. https:\/\/doi.org\/10.1002\/art.40718.","DOI":"10.1002\/art.40718"},{"issue":"5","key":"146_CR33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/art.33453","volume":"64","author":"Y Gong","year":"2012","unstructured":"Gong Y, Zheng N, Chen SB, et al. Ten years\u2019 experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum. 2012;64(5):1399\u2013406.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"146_CR34","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/annrheumdis-2017-211989","volume":"77","author":"A de Koning","year":"2018","unstructured":"de Koning A, de Bruin F, van den Berg R, et al. Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. Ann Rheum Dis. 2018;77(2):293\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"146_CR35","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/rheumatology\/kex318","volume":"57","author":"X Baraliakos","year":"2018","unstructured":"Baraliakos X, Regel A, Kiltz U, et al. Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. Rheumatology (Oxford). 2018;57(9):1541\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"6 Suppl 74","key":"146_CR36","first-page":"24","volume":"30","author":"E Roussou","year":"2012","unstructured":"Roussou E, Ciurtin C. Clinical overlap between fibromyalgia tender points and enthesitis sites in patients with spondyloarthritis who present with inflammatory back pain. Clin Exp Rheumatol. 2012;30(6 Suppl 74):24\u201330.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"146_CR37","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1002\/art.40185","volume":"69","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane GJ, Barnish MS, Pathan E, et al. Co-occurrence and characteristics of patients with axial spondyloarthritis who meet criteria for fibromyalgia: results from a UK National Register. Arthritis Rheumatol. 2017;69(11):2144\u201350.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"146_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73(1):101\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"146_CR39","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3899\/jrheum.150721","volume":"43","author":"FP Kroon","year":"2016","unstructured":"Kroon FP, van der Burg LR, Ramiro S, et al. Nonsteroidal antiinflammatory drugs for axial spondyloarthritis: a Cochrane review. J Rheumatol. 2016;43(3):607\u201317.","journal-title":"J Rheumatol"},{"issue":"9894","key":"146_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769\u201379.","journal-title":"Lancet"},{"key":"146_CR41","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.","journal-title":"BMJ"},{"issue":"8","key":"146_CR42","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/j.1572-0241.2000.02263.x","volume":"95","author":"GF Bonner","year":"2000","unstructured":"Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95(8):1946\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"146_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","volume":"56","author":"X Baraliakos","year":"2017","unstructured":"Baraliakos X, Kiltz U, Peters S, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2017;56(1):95\u2013102.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"146_CR44","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/ard.2004.029728","volume":"64","author":"A Wanders","year":"2005","unstructured":"Wanders A, Landewe R, Dougados M, Mielants H, van der Linden S, van der Heijde D. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis. 2005;64(7):988\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"146_CR45","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2\u00a0years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"146_CR46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/annrheumdis-2012-203055","volume":"73","author":"H Haibel","year":"2014","unstructured":"Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis. 2014;73(1):243\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"146_CR47","first-page":"659","volume":"23","author":"J Braun","year":"1996","unstructured":"Braun J, Bollow M, Seyrekbasan F, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol. 1996;23(4):659\u201364.","journal-title":"J Rheumatol"},{"issue":"9","key":"146_CR48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/ard.2006.052878","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J, Zochling J, Baraliakos X, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 2006;65(9):1147\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"146_CR49","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/ard.2006.054098","volume":"66","author":"H Haibel","year":"2007","unstructured":"Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis. 2007;66(3):419\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"146_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.berh.2006.03.003","volume":"20","author":"N Akkoc","year":"2006","unstructured":"Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol. 2006;20(3):539\u201357.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"146_CR51","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/14712598.2018.1468884","volume":"18","author":"A Jones","year":"2018","unstructured":"Jones A, Ciurtin C, Ismajli M, Leandro M, Sengupta R, Machado PM. Biologics for treating axial spondyloarthritis. Expert Opin Biol Ther. 2018;18(6):641\u201352.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"146_CR52","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"146_CR53","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68(2):282\u201398.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"146_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"146_CR55","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702\u201312.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"146_CR56","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"146_CR57","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados M, van der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(8):2091\u2013102.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"146_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73(1):39\u201347.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"146_CR59","doi-asserted-by":"publisher","first-page":"e000524","DOI":"10.1136\/rmdopen-2017-000524","volume":"3","author":"V Navarro-Compan","year":"2017","unstructured":"Navarro-Compan V, Plasencia-Rodriguez C, de Miguel E, Diaz Del Campo P, Balsa A, Gratacos J. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open. 2017;3(2):e000524.","journal-title":"RMD Open"},{"issue":"7","key":"146_CR60","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/annrheumdis-2017-211313","volume":"77","author":"MA Brown","year":"2018","unstructured":"Brown MA, Bird PA, Robinson PC, et al. Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study. Ann Rheum Dis. 2018;77(7):1091\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"146_CR61","doi-asserted-by":"publisher","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","volume":"1","author":"JR Maneiro","year":"2015","unstructured":"Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1(1):e000017.","journal-title":"RMD Open"},{"issue":"1","key":"146_CR62","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13075-017-1493-8","volume":"19","author":"N Ghosh","year":"2017","unstructured":"Ghosh N, Ruderman EM. Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance. Arthritis Res Ther. 2017;19(1):286.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"146_CR63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/ar4561","volume":"16","author":"PC Robinson","year":"2014","unstructured":"Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther. 2014;16(3):109.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"146_CR64","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3899\/jrheum.170477","volume":"45","author":"ID Flouri","year":"2018","unstructured":"Flouri ID, Markatseli TE, Boki KA, et al. Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts longterm drug persistence. J Rheumatol. 2018;45(6):785\u201394.","journal-title":"J Rheumatol"},{"issue":"7","key":"146_CR65","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"146_CR66","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/rheumatology\/kex457","volume":"57","author":"F Yahya","year":"2018","unstructured":"Yahya F, Gaffney K, Hamilton L, et al. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort. Rheumatology (Oxford). 2018;57(4):619\u201324.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"146_CR67","doi-asserted-by":"publisher","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3\u00a0years of continuous treatment with infliximab. Arthritis Res Ther. 2005;7(3):R439\u201344.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"146_CR68","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/rheumatology\/kew269","volume":"55","author":"W Fong","year":"2016","unstructured":"Fong W, Holroyd C, Davidson B, et al. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2016;55(10):1837\u201342.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"146_CR69","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645\u201354.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"146_CR70","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","volume":"77","author":"C Molnar","year":"2018","unstructured":"Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2018;77(1):63\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"146_CR71","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/art.38068","volume":"65","author":"P Machado","year":"2013","unstructured":"Machado P. Anti-tumor necrosis factor and new bone formation in ankylosing spondylitis: the controversy continues. Arthritis Rheum. 2013;65(10):2537\u201340.","journal-title":"Arthritis Rheum"},{"issue":"26","key":"146_CR72","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"146_CR73","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2017;76(3):571\u201392.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"146_CR74","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL, et al. Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol. 2016;68(12):2901\u201310.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"146_CR75","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"146_CR76","doi-asserted-by":"publisher","first-page":"e000592","DOI":"10.1136\/rmdopen-2017-000592","volume":"3","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open. 2017;3(2):e000592.","journal-title":"RMD Open"},{"issue":"2","key":"146_CR77","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","volume":"75","author":"X Baraliakos","year":"2016","unstructured":"Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75(2):408\u201312.","journal-title":"Ann Rheum Dis"},{"key":"146_CR78","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16\u00a0week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351.","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"146_CR79","doi-asserted-by":"publisher","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: 16 week results of a phase 3 randomized, double-blind, placebo controlled trial in patients with prior inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2018. https:\/\/doi.org\/10.1002\/art.40753.","DOI":"10.1002\/art.40753"},{"issue":"9","key":"146_CR80","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, Ostergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295\u2013302.","journal-title":"Ann Rheum Dis"},{"key":"146_CR81","doi-asserted-by":"crossref","unstructured":"Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258\u201370.","DOI":"10.1002\/art.40728"},{"key":"146_CR82","doi-asserted-by":"publisher","unstructured":"Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis. 2018. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213654.","DOI":"10.1136\/annrheumdis-2018-213654"},{"issue":"8","key":"146_CR83","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340\u20137.","journal-title":"Ann Rheum Dis"},{"key":"146_CR84","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378\u201387.","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"146_CR85","doi-asserted-by":"crossref","unstructured":"McInnes IB, Siebert S. The extending scope of kinase inhibition in immune diseases. Lancet. 2018;392(10162):2328\u201331.","DOI":"10.1016\/S0140-6736(18)32600-X"},{"issue":"3","key":"146_CR86","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.38967","volume":"67","author":"ME Costello","year":"2015","unstructured":"Costello ME, Ciccia F, Willner D, et al. Brief report: intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol. 2015;67(3):686\u201391.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"146_CR87","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.berh.2015.08.001","volume":"29","author":"ME Costello","year":"2015","unstructured":"Costello ME, Robinson PC, Benham H, Brown MA. The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. Best Pract Res Clin Rheumatol. 2015;29(2):202\u201312.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"146_CR88","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/rheumatology\/kev218","volume":"54","author":"TJ Kenna","year":"2015","unstructured":"Kenna TJ, Robinson PC, Haroon N. Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis. Rheumatology (Oxford). 2015;54(9):1549\u201356.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-019-0146-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-019-0146-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-019-0146-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:39:17Z","timestamp":1724456357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-019-0146-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1007\/s40744-019-0146-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"4 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}